Proactiveinvestors recommends
Stocktube video
20/08/2012

Tissue Regenix MD says the company is at an "exciting period"

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: TRX
1 year chart More charts
digital-look imported chart image
Deal TRX Tax Free*
*subject to change and depends on individual circumstances.
1 day chart More charts
digital-look imported chart image
Advertisement
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Tissue Regenix
www.tissueregenix.com
Deal Tissue Regenix Tax Free* Losses can exceed
your initial deposit *subject to change and depends on individual circumstances.

Tissue Regenix is a company that focuses on delivering practical solutions to real clinical issues using its patented dCELL® process. The dCELL® Process removes foreign cells & DNA and provides a matrix that repopulates with patients own cells once its implanted - integrating into the patients own tissues.

Full Tissue Regenix profile here
Pdf

Tissue Regenix to unveil pre-clinical trial data later this year

July 30 2012, 4:15pm Chief executive Antony Odell said that the company may file for approval for commercial launch as early as 2014.

Tissue Regenix (LON:TRX) is to unveil data from a pre-clinical trial for the treatment of torn meniscus cartilage in knees later this year, chief executive Antony Odell told Bloomberg.

The regenerative tissue firm, which has pioneered a technology to swap worn out or damaged body tissue with replacements from a human donor or animal, added that a trial in humans will kick off in 2013.

Odell said that the company may file for approval for commercial launch as early as 2014.

The meniscus refers to either of the two parts of the knee’s cartilage, which provide structural support to the knee when it is put under pressure.

An injury to one of the ‘menisci’ is common, especially in sport, where it is often referred to as “torn cartilage”.

Tissue Regenix hopes its dCell treatment can revolutionise the recovery process for such injuries.

The dCell technology removes cellular material from animal tissue so that the recipient does not reject the implant.

The company is also working on replacement heart valves, skin and vascular patches using dCell in addition to cartilage and ligaments.

Shares in the company rose almost 7 per cent to 9.75 pence.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.